(GLPG) Galapagos - Ratings and Ratios
CAR-T, Oncology, Immunology, Pipeline, Trials
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 29.9% |
| Value at Risk 5%th | 45.9% |
| Relative Tail Risk | -6.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -3.54 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.314 |
| Beta | 0.137 |
| Beta Downside | 0.332 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.26% |
| Mean DD | 31.13% |
| Median DD | 36.18% |
Description: GLPG Galapagos November 11, 2025
Galapagos NV (AS: GLPG) is a Belgium-based biotechnology firm that concentrates on developing novel oncology and immunology medicines for the United States and Europe. Founded in 1999 and listed as a common stock under the ticker GLPG, the company operates within the GICS Biotechnology sub-industry.
The current pipeline features four point-of-care CAR-T programs: GLPG3667 (completed Phase 1b), GLPG5101 (CD19 CAR-T for relapsed/refractory non-Hodgkin lymphoma in Phase 1/2), GLPG5201 (CD19 CAR-T for relapsed/refractory chronic lymphocytic leukemia in Phase 1/2), and GLPG5301 (BCMA CAR-T for relapsed/refractory multiple myeloma in Phase 1/2). All candidates are being advanced with an in-house manufacturing model that aims to reduce supply-chain complexity.
Strategic collaborations with Gilead Sciences and AbbVie provide both upfront payments and potential milestone/royalty streams, helping to offset R&D outlays and broaden market access for eventual commercial products.
From a financial standpoint, Galapagos reported a market capitalization of roughly €10 billion and held about €1.5 billion in cash and equivalents at the end of FY 2023, giving it a runway of 12-18 months at current burn rates. The broader CAR-T market is projected to grow at a CAGR of ~20 % through 2030, driven by increasing adoption of personalized cell therapies and favorable reimbursement trends in the U.S. and EU.
For a deeper, data-driven valuation of GLPG’s upside and downside scenarios, the ValueRay platform provides a granular, model-based analysis worth reviewing.
GLPG Stock Overview
| Market Cap in USD | 2,180m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2005-05-06 |
| Return 12m vs S&P 500 | -4.93% |
| Analyst Rating | - |
GLPG Dividends
Currently no dividends paidGLPG Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -11.67% |
| CAGR/Max DD Calmar Ratio | -0.22 |
| CAGR/Mean DD Pain Ratio | -0.37 |
| Current Volume | 38.9k |
| Average Volume | 75.8k |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-436.0m TTM) > 0 and > 6% of Revenue (6% = 17.2m TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA 1.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 974.3% (prev 1338 %; Δ -364.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -269.4m > Net Income -436.0m (YES >=105%, WARN >=100%) |
| error: Net Debt/EBITDA cannot be calculated |
| Current Ratio 8.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.9m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 84.31% (prev 56.80%; Δ 27.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 7.47% (prev 5.75%; Δ 1.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3300 (EBITDA TTM -274.6m / Interest Expense TTM 97.0k) >= 6 (WARN >= 3) |
Altman Z'' 3.56
| (A) 0.80 = (Total Current Assets 3.16b - Total Current Liabilities 366.6m) / Total Assets 3.51b |
| (B) -0.16 = Retained Earnings (Balance) -577.7m / Total Assets 3.51b |
| (C) -0.08 = EBIT TTM -320.1m / Avg Total Assets 3.84b |
| (D) -0.54 = Book Value of Equity -577.7m / Total Liabilities 1.06b |
| Total Rating: 3.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.11
| 1. Piotroski 1.50pt |
| 2. FCF Yield -15.81% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC (= -17.51)% |
| 7. RoE -16.24% |
| 8. Rev. Trend 5.14% |
| 9. EPS Trend 4.45% |
What is the price of GLPG shares?
Over the past week, the price has changed by -2.00%, over one month by -10.47%, over three months by -2.93% and over the past year by +6.34%.
Is GLPG a buy, sell or hold?
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.7 | 15.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.4 | -8% |
GLPG Fundamental Data Overview November 15, 2025
Market Cap EUR = 1.88b (1.88b EUR * 1.0 EUR.EUR)
P/E Forward = 357.1429
P/S = 6.5573
P/B = 0.7287
Beta = -0.05
Revenue TTM = 286.9m EUR
EBIT TTM = -320.1m EUR
EBITDA TTM = -274.6m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.82b EUR (1.88b + (null Debt) - CCE 64.5m)
Interest Coverage Ratio = -3300 (Ebit TTM -320.1m / Interest Expense TTM 97.0k)
FCF Yield = -15.81% (FCF TTM -287.3m / Enterprise Value 1.82b)
FCF Margin = -100.1% (FCF TTM -287.3m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = 84.31% ((Revenue TTM 286.9m - Cost of Revenue TTM 45.0m) / Revenue TTM)
Gross Margin QoQ = 84.76% (prev 92.79%)
Tobins Q-Ratio = 0.52 (Enterprise Value 1.82b / Total Assets 3.51b)
Interest Expense / Debt = unknown (Interest Expense 97.0k / Debt none)
Taxrate = 7.90% (-17.5m / -221.5m)
NOPAT = -294.8m (EBIT -320.1m * (1 - 7.90%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.16b / Total Current Liabilities 366.6m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -274.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -287.3m)
Total Stockholder Equity = 2.68b (last 4 quarters mean from totalStockholderEquity)
RoA = -12.41% (Net Income -436.0m / Total Assets 3.51b)
RoE = -16.24% (Net Income TTM -436.0m / Total Stockholder Equity 2.68b)
RoCE = -11.89% (EBIT -320.1m / Capital Employed (Equity 2.68b + L.T.Debt 7.50m))
RoIC = -10.99% (negative operating profit) (NOPAT -294.8m / Invested Capital 2.68b)
WACC = 6.52% (E(1.88b)/V(1.88b) * Re(6.52%) + (debt-free company))
Discount Rate = 6.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -70.01%
Fair Price DCF = unknown (Cash Flow -287.3m)
EPS Correlation: 4.45 | EPS CAGR: 239.6% | SUE: 0.02 | # QB: 0
Revenue Correlation: 5.14 | Revenue CAGR: -10.01% | SUE: 0.02 | # QB: 0